Lates News

Asia Pharma announced on the Hong Kong Stock Exchange that its revenue for the six months ending on June 30, 2025 totaled RMB 2.34 billion, a decrease of 71.6% year-on-year, mainly due to a decrease in intellectual property income generated in the six months ending on June 30, 2024. The net loss was RMB 5.91 billion, compared to a profit of RMB 1.63 billion in the same period last year, primarily due to the aforementioned decrease in intellectual property income.